Skip to main content
Top
Published in: Pituitary 6/2017

01-12-2017

Pituitary apoplexy and rivaroxaban

Authors: S. Ly, A. Naman, B. Chaufour-Higel, M. Patey, C. Arndt, B. Delemer, C. F. Litre

Published in: Pituitary | Issue 6/2017

Login to get access

Abstract

Pituitary apoplexy (PA), defined by the occurrence of a massive hemorrhagic necrotic rearrangement within a pituitary adenoma, is rare. Its occurrence can be associated with certain risk factors, including anticoagulation. We report the first case of PA with rivaroxaban which is one of the new oral anticoagulants: a 73 year-old patient presenting with severe headache and visual field deterioration. Surgery was performed. Radiotherapy treatment was decided three months after surgery because of tumor residue.
Literature
1.
go back to reference Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani D (2013) New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 70(12):1486–1490PubMed Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani D (2013) New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 70(12):1486–1490PubMed
2.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed
3.
go back to reference Uemura M, Miyashita F, Shimomura R, Fujinami J, Toyoda K (2013) Pituitary apoplexy during treatment with dabigatran. Neurol Clin Neurosci 1:82–83CrossRef Uemura M, Miyashita F, Shimomura R, Fujinami J, Toyoda K (2013) Pituitary apoplexy during treatment with dabigatran. Neurol Clin Neurosci 1:82–83CrossRef
4.
go back to reference Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A (2016) New oral anticoagulants and pituitary apoplexy. Pituitary 19(2):232‑4CrossRef Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A (2016) New oral anticoagulants and pituitary apoplexy. Pituitary 19(2):232‑4CrossRef
5.
go back to reference Doglietto F, Roca E, La Rocca G, Schreiber A, Bolzoni Villaret A, Nicolai P et al (2017) New oral anticoagulants and pituitary apoplexy. World Neurosurg 100:700CrossRefPubMed Doglietto F, Roca E, La Rocca G, Schreiber A, Bolzoni Villaret A, Nicolai P et al (2017) New oral anticoagulants and pituitary apoplexy. World Neurosurg 100:700CrossRefPubMed
Metadata
Title
Pituitary apoplexy and rivaroxaban
Authors
S. Ly
A. Naman
B. Chaufour-Higel
M. Patey
C. Arndt
B. Delemer
C. F. Litre
Publication date
01-12-2017
Publisher
Springer US
Published in
Pituitary / Issue 6/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0828-4

Other articles of this Issue 6/2017

Pituitary 6/2017 Go to the issue